Mitchell Levy
Marcel Levi
Mark D. Williams
Massimo Antonelli
Dazhe Wang
Mariano Alejandro Mignini

Comprehensive safety analysis of concomitant drotrecogin alfa (activated) and prophylactic heparin use in patients with severe sepsis

Published online: 7 May 2009
© Springer-Verlag 2009

The online version of the original article can be found under doi:[10.1007/s00134-009-1483-7](https://doi.org/10.1007/s00134-009-1483-7).

M. Levy (✉)
Rhode Island Hospital and Brown University Medical School,
593 Eddy St., Providence, RI 02903, USA
e-mail: mitchell_levy@brown.edu

M. Levi
Departments of Vascular Medicine and Internal Medicine,
Academic Medical Center, University of Amsterdam, Amsterdam,
The Netherlands

M. D. Williams · D. Wang
Lilly Research Laboratories, Eli Lilly & Co., Indianapolis, IN, USA

M. Antonelli
Policlinico Universitario A. Gemelli, Università Cattolica del Sacro
Cuore, Rome, Italy

M. A. Mignini
Medical Department of Eli Lilly SpA, Sesto Fiorentino, Italy

Erratum to: Intensive Care Med DOI 10.1007/s00134-009-1483-7

In Table 3 of the manuscript, the row of data that corresponds to patients with platelet count <30,000 has been switched with data for patients with platelet count between 30,000 and 80,000. This is true for both the 6 day and 28 day data.

The revised Table 3 is given here.

Table 3 Subgroup analyses of serious bleeding events

Variable	DrotAA + heparin		DrotAA + placebo		Relative risk ^a	RR 95% CI	Breslow–Day p value
	N	# with SBE (%)	N	# with SBE (%)			
Infusion period (days 0–6)							
Baseline heparin							0.170
No	520	14 (3.0)	481	11 (2.3)	1.31	0.60, 2.85	
Yes	455	8 (1.6)	478	13 (2.7)	0.58	0.24, 1.39	
Baseline platelet count class							0.348
<30,000/mm ³	6	1 (16.7)	8	0 (0.0)	3.86	0.18, 80.99	
30,000–80,000/mm ³	175	7 (4.0)	148	5 (3.4)	1.18	0.38, 3.65	
>80,000/mm ³	789	14 (1.8)	797	19 (2.4)	0.74	0.38, 1.47	
Not applicable	5	0 (0.0)	6	0 (0.0)	–	–	
Recent surgery (within 7 days)							0.374
No	639	12 (1.9)	627	16 (2.6)	0.74	0.35, 1.54	
Yes	330	10 (3.0)	331	8 (2.4)	1.25	0.50, 3.14	
Missing or unknown	6	0 (0.0)	1	0 (0.0)	–	–	
Number of baseline organ dysfunction							0.290
0	12	0 (0.0)	7	0 (0.0)	–	–	
1	64	0 (0.0)	69	1 (1.4)	0.36	0.01, 8.66	
2	274	3 (1.1)	272	10 (3.7)	0.30	0.08, 1.07	

Table 3 continued

Variable	DrotAA + heparin		DrotAA + placebo		Relative risk ^a	RR 95% CI	Breslow–Day p value
	N	# with SBE (%)	N	# with SBE (%)			
3	313	7 (2.2)	327	5 (1.5)	1.46	0.47, 4.56	
4	203	5 (2.5)	199	3 (1.5)	1.63	0.40, 6.75	
5	81	6 (7.4)	65	4 (6.2)	1.20	0.35, 4.09	
6	23	0 (0.0)	18	1 (5.6)	0.26	0.01, 6.12	
7	5	1 (20.0)	2	0 (0.0)	1.50	0.08, 26.86	
Type of baseline organ dysfunction							
Baseline vasopressor use	844	35 (4.1)	816	44 (5.4)	0.77	0.50, 1.19	
Baseline ventilator use	845	22 (2.6)	858	21 (2.4)	1.06	0.59, 1.92	
Baseline liver dysfunction	87	4 (4.6)	71	2 (2.8)	1.63	0.31, 8.65	
Baseline CNS dysfunction	272	6 (2.2)	247	6 (2.4)	0.91	0.30, 2.78	
Baseline metabolic acidosis dysfunction	294	12 (4.1)	275	8 (2.9)	1.40	0.58, 3.38	
Baseline renal dysfunction	418	11 (2.6)	414	12 (2.9)	0.91	0.41, 2.03	
28-day study period (days 0–28)							
Baseline heparin							0.142
No	520	23 (4.4)	525	23 (4.4)	1.01	0.57, 1.86	
Yes	455	17 (3.4)	434	27 (6.2)	0.53	0.31, 0.99	
Baseline platelet count class							0.377
<30,000/mm ³	6	1 (16.7)	8	0 (0.0)	3.86	0.18, 80.99	
30,000–80,000/mm ³	175	9 (5.1)	148	11 (7.4)	0.69	0.29, 1.62	
>80,000/mm ³	789	28 (3.5)	797	39 (4.9)	0.73	0.45, 1.17	
Not applicable	5	0 (0.0)	6	0 (0.0)	–	–	
Recent surgery (within 7 days)							0.194
No	639	21 (3.3)	627	34 (5.4)	0.61	0.36, 1.03	
Yes	330	17 (5.2)	331	16 (4.8)	1.07	0.55, 2.07	
Missing or unknown	6	0 (0.0)	1	0 (0.0)	–	–	
Number of baseline organ dysfunction							0.437
0	12	0 (0.0)	7	0 (0.0)	–	–	
1	64	1 (1.6)	69	2 (2.9)	0.54	0.05, 5.80	
2	274	4 (1.5)	272	15 (5.5)	0.26	0.09, 0.79	
3	313	13 (4.2)	327	17 (5.2)	0.80	0.39, 1.62	
4	203	11 (5.4)	199	9 (4.5)	1.20	0.51, 2.83	
5	81	7 (8.6)	65	6 (9.2)	0.94	0.33, 2.65	
6	23	1 (4.3)	18	1 (5.5)	0.78	0.05, 11.67	
7	5	1 (20.0)	2	0 (0.0)	1.50	0.08, 26.86	
Type of baseline organ dysfunction							
Baseline vasopressor use	844	35 (4.1)	816	44 (5.4)	0.77	0.50, 1.19	
Baseline ventilator use	845	36 (4.3)	858	47 (5.5)	0.78	0.51, 1.19	
Baseline liver dysfunction	87	8 (9.2)	71	3 (4.2)	2.18	0.60, 7.90	
Baseline CNS dysfunction	272	9 (3.3)	247	12 (4.9)	0.68	0.29, 1.59	
Baseline metabolic acidosis dysfunction	294	20 (6.8)	275	15 (5.5)	1.25	0.65, 2.39	
Baseline renal dysfunction	418	22 (5.3)	414	23 (5.6)	0.95	0.54, 1.67	

SBE Serious bleeding event, CNS central nervous system

^a Calculated by Cochran–Mantel Haenszel statistics adjusted logit relative risk